Eisai is an API and finished-dose manufacturer based in Japan. It appears in 526 regulatory filings across 26 regulators, without an active US DMF or CEP on file. Its filings concentrate with AIFA (IT), Health Canada and FAMHP (BE). Its GMP standing is certified by ZLG (DE), MFDS (Korea) and HSA (SG), among 6 authorities.
| Site | FDA FEI |
|---|---|
| Raleigh, United Arab Emirates | Not on file |
| Zürich, Switzerland | Not on file |
| Frankfurt Am Main, Germany | Not on file |
| Frankfurt, Germany | Not on file |
| HATFIELD, United Kingdom | Not on file |
| -, Indonesia | Not on file |
4 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Eribulin | SFDA (Saudi Arabia) | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| AIFA (IT) | 74 | None |
| Health Canada | 61 | None |
| FAMHP (BE) | 56 | None |
| BPOM (ID) | 32 | None |
| EMA | 28 | 1 |
| AEMPS (ES) | 27 | None |
| ZLG (DE) | None | 4 |
| MFDS (Korea) | None | 2 |
| HSA (SG) | None | 2 |
| MHRA (UK) | None | 2 |
| ANVISA (Brazil) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | $478K | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Choose your molecules and target markets. Eisai comes back tiered against every other supplier able to file there.
Start for free